Elucid Bioimaging Says Co Is Aware Of A Lawsuit Filed By Heartflow, On October 22, 2026. Elucid Will Respond To And Defend Against The Claims In The Lawsuit Through The Appropriate Legal Channels

Elucid Bioimaging Inc. ("Elucid") today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products.

Elucid is aware of a lawsuit filed by Heartflow, Inc., on October 22, 2026. Elucid will respond to and defend against the claims in the lawsuit through the appropriate legal channels.

"Elucid was founded to help physicians predict cardiovascular risk and personalize prevention for each patient, so that more heart attacks and strokes can be avoided," said Kelly Huang, PhD, CEO of Elucid. "We fully believe in the uniqueness of our products and technology, we are confident in their independent development, and we have invested substantially for over a decade in building a robust intellectual property portfolio. Our commitment to patients and physicians is unchanged, and we remain focused on supporting the clinicians and care teams who seek better solutions for patient care."

That commitment is reflected in Elucid’s technology. Elucid, an innovator of AI-powered cardiovascular imaging software, seeks to advance the standard of care by bringing FFR-IQ™ and Plaque-IQ™ together in a comprehensive clinical platform that integrates coronary anatomy, physiology and plaque biology from a single CCTA, supported by a new interface and reporting workflow. This integration supports lesion-specific assessment and personalized medical and interventional decisions.